S-1: Picard Medical Registers 17M Shares for Resale

Picard Medical, Inc. filed an S-1 registration statement for the resale of up to 17 million shares of common stock by selling stockholders, stemming from a recent $15 million senior secured notes and warrants private placement.

Summary

• Picard Medical, Inc. filed an S-1 registration statement for the resale of up to 17,000,000 shares of common stock by HT Investments MA LLC and High Trail Special Situations LLC (the Selling Stockholders).
• The shares include 7,009,346 shares issuable upon exercise of warrants (initial exercise price $2.675 per share) and 9,990,654 shares issuable upon conversion or settlement of senior secured notes due December 26, 2028.
• The company will not receive any proceeds from the sale of shares by the Selling Stockholders, but may receive proceeds from cash exercise of warrants, which will be used for general corporate purposes.
• The underlying transaction is a private placement entered into on December 24, 2025, where Picard Medical issued $15,000,000 in senior secured notes and warrants.
• The facility allows for up to an additional $35,000,000 of notes to be issued in subsequent closings prior to December 15, 2028, subject to conditions and Selling Stockholders' consent.
• The notes are senior secured obligations with a first-priority security interest in substantially all of the company's tangible and intangible assets.
• The company operates through its wholly-owned subsidiary, SynCardia Systems, LLC, which manufactures and sells the SynCardia total artificial heart (STAH), the only FDA and Health Canada approved implantable total artificial heart as a bridge to heart transplantation for biventricular heart failure patients.
• Over 2,100 STAHs have been implanted in 27 countries.
• The company's strategy includes product innovation (e.g., 'Emperor' a next-generation, driver-less, fully implantable STAH), commercial expansion, and deepening customer engagement.
• Common stock is listed on NYSE American under symbol PMI, with a closing price of $1.76 on January 8, 2026.

Sentiment

Score: 5

Explanation: The filing details a significant financing event that provides capital but also introduces substantial potential dilution and senior secured debt. While the company has a unique, FDA-approved product and a clear innovation strategy, the immediate financial impact for existing shareholders from the resale and the conditions for future funding present notable risks.

Positives

• Secured $15,000,000 in initial senior secured notes, with potential for an additional $35,000,000, providing capital for operations.
• The company manufactures the SynCardia total artificial heart (STAH), the only FDA and Health Canada approved implantable total artificial heart for biventricular heart failure as a bridge to transplant.
• Over 2,100 STAHs have been implanted in 27 countries, indicating established market presence and clinical experience.
• Strategic focus on product innovation, including the 'Emperor' (next-generation, driver-less, fully implantable STAH), and expanding commercial reach.
• Maintains an ISO 13485-certified quality management system and manufacturing capacity for approximately 450 total artificial hearts per year.

Negatives

• The resale of up to 17,000,000 shares by Selling Stockholders, and potential future issuances, will dilute existing stockholders' economic and voting interests.
• The company will not receive any proceeds from the sale of shares by the Selling Stockholders, only from potential cash exercise of warrants.
• Access to the full $35,000,000 additional financing under the Purchase Agreement is subject to the Selling Stockholders' consent and satisfaction of specified conditions, which are not guaranteed.
• Issuance of shares upon conversion of notes or exercise of warrants is subject to stock exchange limitations and beneficial ownership caps (initial 9.99%), requiring stockholder approval to exceed, which has not yet been obtained.
• The senior secured notes are backed by a first-priority security interest in substantially all of the company's tangible and intangible assets, placing noteholders' claims ahead of equity in a downside scenario.
• Restrictions in the Purchase Agreement could limit the company's ability to pursue alternative equity-linked financing.
• The company may require additional financing beyond the Purchase Agreement to sustain operations.
• The independent auditor's report (incorporated by reference) contains an explanatory paragraph regarding the company's ability to continue as a going concern.

Risks

• The resale of shares of common stock by the Selling Stockholders, including shares issuable upon conversion of senior secured notes and upon exercise of warrants, may depress the market price of common stock.
• The potential issuance of additional shares in connection with these securities will dilute existing stockholders.
• Sales to the Selling Stockholders could result in substantial dilution to the interests of other holders of common stock.
• The sale of a substantial number of shares, or the anticipation of such sales, could make it more difficult to sell equity or equity-related securities in the future at a time and price that might otherwise be desired.
• It is not possible to predict the actual number of shares of common stock that may be sold to the Selling Stockholders or the actual gross proceeds resulting from those sales.
• The number of shares of common stock that may be issued upon conversions of, or amortization share settlements under, the Notes or upon exercises of the Warrants will fluctuate based on the market price of common stock at the time of any such issuances and other variables.
• Investors who buy shares at different times will likely pay different prices and may therefore experience different levels of dilution and investment outcomes.
• Management will have broad discretion over the use of any net proceeds from the sale of shares to the Selling Stockholders, and there is no guarantee of successful investment.
• The company may not have access to the full amount available under the Purchase Agreement, as draws after the initial closing are subject to the Selling Stockholders' consent and satisfaction or waiver of specified closing conditions.
• Stock exchange limitations and beneficial ownership caps (initial 9.99%) may delay or prevent share-settled financings or redemptions until requisite stockholder approval is obtained.
• Restrictions in the Purchase Agreement and related transaction documents could limit the company's flexibility to raise capital when needed or on acceptable terms.
• Even with the full utilization of the Purchase Agreement, additional capital may be required to fund business plans and working capital needs, potentially requiring further dilutive or senior financings.
• The senior secured notes are supported by first-priority security interests in substantially all assets, which could adversely affect stockholders by placing noteholders' claims ahead of equity in a downside scenario and restricting operational/financing activities.
• The prospectus may disrupt current plans and operations as a result of the announcement and consummation of the transactions described.
• The ability to recognize the anticipated benefits of the transactions described may be affected by competition and the ability to grow and manage growth profitably.
• Costs are related to this prospectus and the transactions described.
• The ability to acquire additional working capital on reasonable terms, as needed and on a timely basis, is a risk.
• Market conditions may affect the stock price and operating results.
• The ability to maintain competitive technological advantages against competitors in the industry is a risk.
• The ability to maintain, protect, and enhance intellectual property is a risk.
• The effects of increased competition in the market and the ability to compete effectively are risks.
• Costs are associated with defending intellectual property infringement and other claims.
• Expectations concerning relationships with suppliers, partners, and other third parties are subject to risk.
• The ability to comply with evolving legal standards and regulations, particularly concerning requirements for being a public company and environmental regulations, is a risk.
• Certain provisions of the Charter, Bylaws, and Delaware law could make it more difficult to acquire the company by means of a tender offer, a proxy contest, or otherwise, or to remove incumbent officers and directors.
• Authorized but unissued shares are available for future issuance without stockholder approval, which could make it more difficult or discourage an attempt to obtain control of the company.

Future Outlook

The company's strategy is to advance product innovation, expand commercial reach, and deepen customer engagement while driving scale and operating leverage. Key priorities include developing a next-generation, driver-less, fully implantable version of the STAH (referred to as 'Emperor'), next-generation portable and hospital drivers, and continuing surgeon and center training to support safe adoption and expand sales in existing and new geographies.

Management Comments

• Our strategy, consistent with our prior filing, is to advance product innovation, expand our commercial reach and deepen customer engagement while driving scale and operating leverage.
• Key priorities include developing a next generation, diver-less and fully implantable version of the STAH referred to as Emperor, next-generation portable and hospital drivers, continuing surgeon and center training to support safe adoption to expand our sales and channel presence in existing and new geographies.

Industry Context

Picard Medical operates in the advanced heart failure market, specifically with its SynCardia total artificial heart (STAH), which is the only FDA and Health Canada approved implantable total artificial heart as a bridge to heart transplantation for biventricular heart failure. This positions the company in a niche but critical segment of the medical device industry, facing competition from other mechanical circulatory support devices and heart transplant programs. The focus on developing a fully implantable, driver-less system ('Emperor') indicates a move towards less invasive and more patient-friendly solutions, aligning with broader trends in medical technology for improved quality of life.

Comparison to Industry Standards

• The SynCardia total artificial heart (STAH) is highlighted as the only implantable total artificial heart approved by the U.S. FDA and Health Canada as a bridge to heart transplantation for patients with biventricular heart failure, setting it apart from competitors in this specific niche.
• The company's manufacturing facility is ISO 13485-certified, which is a recognized international standard for quality management systems in the medical device industry, indicating adherence to high quality and regulatory compliance.
• The development of a 'driver-less and fully implantable' version of the STAH, named 'Emperor,' suggests an effort to innovate beyond current market offerings and potentially set new standards for patient mobility and quality of life compared to existing external driver systems.

Corporate Governance

Related Party Transactions

• The Purchase Agreement for senior secured notes and warrants is with HT Investments MA LLC and High Trail Special Situations LLC, which are managed by Hudson Bay Capital Management LP. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. These entities are the 'Selling Stockholders' and are significant investors.
• Previous convertible notes and short-term loan agreements with 'Fang Family Fund II, LLC' and related parties (Richard Fang, Fang Family Fund, LLC, Dr. Chang You Zhou, Nanyan Zheng, Xiaohong Shang) are listed in the exhibits, indicating ongoing financial relationships.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the potential resale of 17,000,000 shares and future issuances from the notes and warrants. The senior secured nature of the debt places equity holders at a lower priority in a downside scenario.
• Noteholders/Warrantholders (Selling Stockholders): Gain a senior secured position and the ability to resell shares, potentially realizing profits. They also have participation rights in future financings.
• Patients: Continued development of the STAH and the 'Emperor' project could lead to improved treatment options for biventricular heart failure.
• Employees: The capital raise provides funding to support ongoing operations and strategic initiatives, potentially ensuring job stability and growth opportunities.
• Customers (Medical Centers): Continued product innovation and clinical support enhance the value proposition for medical centers using the STAH.

Next Steps

• Selling Stockholders may sell shares from time to time after the registration statement becomes effective.
• The company expects to submit proposals to stockholders at a special meeting to approve the issuance of shares underlying the notes and warrants and to approve an increase in authorized common stock.
• The company intends to use any proceeds from warrant exercises for general corporate purposes.
• Development of a next-generation, driver-less, fully implantable STAH ('Emperor') and next-generation portable and hospital drivers.
• Continuing surgeon and center training to support safe adoption and expand sales.

Key Dates

Recommendation

While Picard Medical possesses a unique, FDA-approved medical device and has a clear strategy for innovation, the immediate financial implications of this S-1 filing warrant caution. The significant potential dilution from the resale of 17 million shares, coupled with the senior secured nature of the new debt and the conditions for accessing additional capital, creates considerable downside risk for existing shareholders. The company's ability to execute its growth strategy and achieve profitability will be critical, but the current structure suggests a 'hold' position until there is clearer evidence of successful integration of the new financing without excessive dilution and progress on the 'Emperor' project. The going concern explanatory paragraph from the auditor also adds a layer of uncertainty.

Keywords

Picard Medical, SynCardia, Total Artificial Heart, STAH, Medical Technology, SEC Filing, S-1, Resale Registration, Senior Secured Notes, Warrants, Dilution, Heart Failure, Bridge to Transplant, FDA Approved, Health Canada Approved, Medical Devices, Capital Raise, NYSE American, PMI